Psychopharmacology

, Volume 217, Issue 2, pp 279–287 | Cite as

Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia

  • Jennifer W. Tidey
  • Damaris J. Rohsenow
  • Gary B. Kaplan
  • Robert M. Swift
  • Netesha Reid
Original Investigation

Abstract

Rationale

Individuals with schizophrenia have high smoking-related morbidity and mortality rates and need powerful and innovative smoking cessation interventions.

Objectives

This proof-of-concept study investigated the feasibility and initial efficacy of combining a contingency management intervention with bupropion to reduce smoking in people with schizophrenia.

Methods

Using a double-blind, placebo-controlled, between-groups design, 57 non-treatment-seeking participants were randomized to receive 300 mg/day bupropion or placebo. One week later, participants were randomized to a contingency management (CM) intervention in which reductions in urinary cotinine levels were reinforced, or a non-contingent reinforcement (NR) condition in which session attendance was reinforced, regardless of cotinine level. Over the 22-day study period, participants visited the laboratory approximately three times per week to provide urine samples for analysis of cotinine levels, to give breath samples for analysis of carbon monoxide (CO) levels, and to report number of cigarettes smoked per day, nicotine withdrawal symptoms, cigarette craving, and psychiatric symptoms.

Results

Cotinine and CO levels significantly decreased during the study period in participants randomized to the CM condition, but not the NR condition. Bupropion did not reduce cotinine levels or increase the efficacy of CM. Cigarette craving and psychiatric symptom levels significantly decreased during the study in all groups.

Conclusions

The results of this study indicate the efficacy and feasibility of this CM intervention for reducing smoking in individuals with schizophrenia.

Keywords

Tobacco dependence Nicotine Psychiatric comorbidity Dual diagnosis Smoking cessation Incentives Craving 

References

  1. Addington J, el-Guebaly N, Campbell W, Hodgins DC, Addington D (1998) Smoking cessation treatment for patients with schizophrenia. Am J Psychiatry 155:974–976PubMedGoogle Scholar
  2. Biener L, Abrams DB (1991) The Contemplation Ladder: validation of a measure of readiness to consider smoking cessation. Health Psychol 10:360–365PubMedCrossRefGoogle Scholar
  3. Brown S, Kim M, Mitchell C, Inskip H (2010) Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 196:116–121PubMedCrossRefGoogle Scholar
  4. Budney AJ, Higgins ST (1998) Treating cocaine dependence: a community reinforcement plus vouchers approach. National Institute on Drug Abuse, RockvilleGoogle Scholar
  5. Carroll KM, Rounsaville BJ (2007) A perfect platform: combining contingency management with medications for drug abuse. Am J Drug Alc Abuse 33:343–365CrossRefGoogle Scholar
  6. Chou KR, Chen R, Lee JF, Ku CH, Lu RB (2004) The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. Int J Nurs Stud 41:321–330PubMedCrossRefGoogle Scholar
  7. Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Lawrence Erlbaum Associates, New JerseyGoogle Scholar
  8. Cox LS, Tiffany ST, Christen AG (2001) Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res 3:7–16PubMedCrossRefGoogle Scholar
  9. Dale LC, Glover ED, Sachs DP, Schroeder DR, Offord KP, Croghan IT, Hurt RD (2001) Bupropion for smoking cessation: predictors of successful outcome. Chest 119:1357–1364PubMedCrossRefGoogle Scholar
  10. de Leon J, Diaz FJ (2005) A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 76:135–57PubMedCrossRefGoogle Scholar
  11. DeMarce JM, Burden JL, Lash SJ, Stephens RS, Grambow SC (2007) Convergent validity of the Timeline Followback for persons with comorbid psychiatric disorders engaged in residential substance use treatment. Addict Behav 32:1582–1592PubMedCrossRefGoogle Scholar
  12. Evins AE, Mays VK, Rigotti NA, Tisdale T, Cather C, Goff DC (2001) A pilot trial of bupropion added to cognitive behavior therapy for smoking cessation in schizophrenia. Nicotine Tob Res 3:397–403PubMedCrossRefGoogle Scholar
  13. Evins AE, Cather C, Deckersbach T, Freudenreich O, Culhane MA, Olm-Shipman CM, Henderson DC, Schoenfeld DA, Goff DC, Rigotti NA (2005) A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychpharmacol 25:218–225CrossRefGoogle Scholar
  14. Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, Freudenreich O, Henderson DC, Schoenfeld DA, Rigotti NA, Goff DC (2007) A 12-week double-blind, placebo-controlled study of bupropion-SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol 27:380–386PubMedCrossRefGoogle Scholar
  15. Fahn S, Elton RL, UPDRS Development Committee (1987) Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson's disease. Florham Park, Macmillan, pp 153–163Google Scholar
  16. Finlay JM, Zigmond MJ (1997) The effects of stress on central dopaminergic neurons: possible clinical implications. Neurochem Res 22:1387–1394PubMedCrossRefGoogle Scholar
  17. First MB, Spitzer RL, Gibbon M, Williams JBW (1994) Structured clinical interview for DSM-IV Axis-I Disorders. Biometrics Research Dept., NY State Psychiatric Inst., NY NYGoogle Scholar
  18. Gallagher SM, Penn PE, Schindler E, Layne W (2007) A comparison of smoking cessation treatments for persons with schizophrenia and other serious mental illnesses. J Psychoactive Drugs 39:487–497PubMedGoogle Scholar
  19. George TP, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkel J, Rounsaville BJ, Kosten TR (2000) Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 157:1835–1842PubMedCrossRefGoogle Scholar
  20. George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, Kosten TR (2002) A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biolog Psychiatry 52:53–61CrossRefGoogle Scholar
  21. George TP, Vessicchio JC, Sacco KA, Weinberger AH, Dudas MM, Allen TM, Creeden CL, Potenza MN, Feingold A, Jatlow PI (2008) A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry 63:1092–1096PubMedCrossRefGoogle Scholar
  22. GlaxoSmithKline (2010) Prescribing Information (Zyban—bupropion hydrochloride extended-release tablets). http://us.gsk.com/products/assets/us_zyban.pdf
  23. Gray KM, Carpenter MJ, Baker NL, Hartwell KJ, Lewis AL, Hiott DW, Desas D, Upadhyaya HP (2011) Bupropion SR and contingency management for adolescent smoking cessation. J Sub Ab Res 40:77–86Google Scholar
  24. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO (1991) The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 86:1119–1127PubMedCrossRefGoogle Scholar
  25. Heil SH, Higgins ST, Bernstein IM, Solomon LJ, Rogers RE, Thomas CS, Badger GJ, Lynch ME (2008) Effects of voucher-based incentives on abstinence from cigarette smoking and fetal growth among pregnant women. Addiction 103:1009–1018PubMedCrossRefGoogle Scholar
  26. Hennekens CH, Hennekens AR, Hollar D, Casey DE (2005) Schizophrenia and increased risks of cardiovascular disease. Am Heart J 150:1115–1121PubMedCrossRefGoogle Scholar
  27. Higgins ST, Budney AJ, Bickel WK, Foerg FE, Donham R, Badger GJ (1994) Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry 51:586–576Google Scholar
  28. Higgins ST, Heil SH, Solomon LJ, Bernstein IM, Plebani Lussier J, Lynch ME et al (2004) A pilot study on voucher-based incentives to promote abstinence from cigarette smoking during pregnancy and postpartum. Nicotine Tob Res 6:1015–1020PubMedCrossRefGoogle Scholar
  29. Higgins ST, Heil SH, Badger GJ, Mongeon JA, Solomon LJ, McHale L, Bernstein IM (2007) Biochemical validation of smoking status in pregnant and recently postpartum women. Exp Clin Psychopharmacol 15:58–66PubMedCrossRefGoogle Scholar
  30. Hughes JR, Carpenter MJ (2006) Does smoking reduction increase future cessation and decrease disease risk? A qualitative review. Nicotine Tob Res 8:739–749PubMedCrossRefGoogle Scholar
  31. Hughes JR, Hatsukami DK (1986) Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43:289–294PubMedGoogle Scholar
  32. Kalman D, Morissette SB, George TP (2005) Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict 14:106–123PubMedCrossRefGoogle Scholar
  33. Kay SR, Opler LA, Fiszbein A (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276PubMedGoogle Scholar
  34. Kosten T, Oliveto A, Feingold A, Poling J, Sevarino K, McCance-Katz E, Stine S, Gonzalez G, Gonsai K (2003) Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend 70:315–325PubMedCrossRefGoogle Scholar
  35. Lamb RJ, Morral AR, Galbicka G, Kirby KC, Iguchi MY (2005) Shaping reduced smoking in smokers without cessation plans. Exp Clin Psychopharmacol 13:83–92PubMedCrossRefGoogle Scholar
  36. Lamb RJ, Kirby KC, Morral AR, Galbicka G, Iguchi MY (2010) Shaping smoking cessation in hard-to-treat smokers. J Consult Clin Psychol 78:62–71PubMedCrossRefGoogle Scholar
  37. National Institute of Mental Health (NIMH) (1976) Abnormal involuntary movement scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology, Rev. 1976. NIMH, Psychopharmacology Research Branch, Division of Basic Brain and Behavioral Sciences, Rockville, MDGoogle Scholar
  38. Nino-Gomez J, Carlini S, Nemani K, Cather C, Pratt S, Evins AE (2010) Safety and efficacy of varenicline in schizophrenia: Preliminary data from 12-week trial. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco, Baltimore, MDGoogle Scholar
  39. Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799–812CrossRefGoogle Scholar
  40. Parks J, Svendsen D, Singer P, Foti M, Mauer B (2006) Morbidity and mortality in people with serious mental illness. National Association of State Mental Health Program Directors, www.nasmhpd.org
  41. Perkins KA, Lerman C, Stitzer M, Fonte CA, Briski JL, Scott JA, Chengappa KN (2008) Development of procedures for early screening of smoking cessation medications in humans. Clin Pharmacol Ther 84:216–221PubMedCrossRefGoogle Scholar
  42. Perkins KA, Lerman C, Fonte CA, Mercincavage M, Stitzer ML, Chengappa KN, Jain A (2010) Cross-validation of a new procedure for early screening of smoking cessation medications in humans. Clin Pharmacol Ther 88:109–14PubMedCrossRefGoogle Scholar
  43. Poling J, Oliveto A, Petry N, Sofuoglu M, Gonsai K, Gonzalez G, Martell B, Kosten TR (2006) Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry 63:219–228PubMedCrossRefGoogle Scholar
  44. Roll JM, Higgins ST, Steingard S, McGinley M (1998) Use of monetary reinforcement to reduce the cigarette smoking of persons with schizophrenia: a feasibility study. Exp Clin Psychopharmacol 6:157–161PubMedCrossRefGoogle Scholar
  45. Saha S, Chant D, McGrath J (2007) A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? Arch Gen Psychiatry 64:1123–1131PubMedCrossRefGoogle Scholar
  46. Sobell LC, Sobell MB (1992) Timeline followback: a technique for assessing self-reported alcohol consumption. In: Litten RZ, Allen J (eds) Measuring alcohol consumption: psychosocial and biological methods. Humana, New Jersey, pp 41–72CrossRefGoogle Scholar
  47. SRNT Subcommittee on Biochemical Verification (2002) Biochemical verification of tobacco use and cessation. Nicotine Tob Res 4:149–159CrossRefGoogle Scholar
  48. Steinberg ML, Ziedonis DM, Krejci JA, Brandon TH (2004) Motivational interviewing with personalized feedback: a brief intervention for motivating smokers with schizophrenia to seek treatment for tobacco dependence. J Consult Clin Psychol 72:723–728PubMedCrossRefGoogle Scholar
  49. Stitzer ML, Bigelow GE (1982) Contingent reinforcement for reduced carbon monoxide levels in cigarette smokers. Addict Behav 7:403–412PubMedCrossRefGoogle Scholar
  50. Stitzer ML, Bigelow GE (1984) Contingent reinforcement for carbon monoxide reduction: within-subject effects of pay amount. J Appl Behav Anal 17:477–83PubMedCrossRefGoogle Scholar
  51. Stitzer ML, Bigelow GE (1985) Contingent reinforcement for reduced breath carbon monoxide levels: target-specific effects on cigarette smoking. Addict Behav 10:345–349PubMedCrossRefGoogle Scholar
  52. Tevyaw T, Colby SM, Tidey JW, Kahler C, Rohsenow DJ, Barnett NP, Monti PM (2009) Contingency management and motivational enhancement: a randomized clinical trial for college student smokers. Nicotine Tob Res 11:739–749PubMedCrossRefGoogle Scholar
  53. Tidey JW, Rohsenow DJ (2009a) Intention to quit moderates the effects of bupropion on smoking urge. Nicotine Tob Res 11:308–312CrossRefGoogle Scholar
  54. Tidey JW, Rohsenow DJ (2009b) Smoking expectancies and intention to quit in smokers with schizophrenia, schizoaffective disorder and non-psychiatric controls. Schiz Res 115:310–316CrossRefGoogle Scholar
  55. Tidey JW, Higgins ST, Bickel WK, Steingard S (1999) Effects of response requirement and the presence of an alternative reinforcer on cigarette smoking by schizophrenics. Psychopharmacol 145:52–60CrossRefGoogle Scholar
  56. Tidey JW, O'Neill SC, Higgins ST (2002) Contingent monetary reinforcement of smoking reductions, with and without transdermal nicotine, in outpatients with schizophrenia. Exp Clin Psychopharmacol 10:241–247PubMedCrossRefGoogle Scholar
  57. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Adolfo AB (2008) Effects of smoking abstinence, smoking cues and nicotine replacement in smokers with schizophrenia and controls. Nicotine Tob Res 10:1047–56PubMedCrossRefGoogle Scholar
  58. Tverdal A, Bjartveit K (2006) Health consequences of reduced daily cigarette consumption. Tob Control 15:472–480PubMedCrossRefGoogle Scholar
  59. Weinberger AH, Reutenauer EL, Allen TM, Termine A, Vessicchio JC, Sacco KA, Easton CJ, McKee SA, George TP (2006) Reliability of the Fagerstrom Test for Nicotine Dependence, Minnesota Nicotine Withdrawal Scale, and Tiffany Questionnaire for Smoking Urges in smokers with and without schizophrenia. Drug Alc Depend 86:278–82CrossRefGoogle Scholar
  60. Williams JM, Steinberg ML, Zimmerman MH, Gandhi KK, Stipelman B, Budsock PD, Ziedonis DM (2010) Comparison of two intensities of tobacco dependence counseling in schizophrenia and schizoaffectivve disorder. J Subst Abuse Treat 38:384–393.Google Scholar
  61. Ziedonis D, Hitsman B, Beckham JC, Zvolensky M, Adler LE, Audrain-McGovern J, Breslau N, Brown RA, George TP, Williams J, Calhoun PS, Riley WT (2008) Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Res 10:1691–1715PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Jennifer W. Tidey
    • 1
  • Damaris J. Rohsenow
    • 1
    • 2
  • Gary B. Kaplan
    • 3
  • Robert M. Swift
    • 1
    • 2
  • Netesha Reid
    • 1
  1. 1.Center for Alcohol and Addiction StudiesBrown UniversityProvidenceUSA
  2. 2.Providence VA Medical CenterProvidenceUSA
  3. 3.VA Boston Healthcare SystemBostonUSA

Personalised recommendations